PMID- 31418622
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20220422
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 32
IP  - 3
DP  - 2021 May
TI  - How do we treat psoriasis patients with hepatitis C infections in real-world 
      situations? A retrospective analysis of 34 patients.
PG  - 321-327
LID - 10.1080/09546634.2019.1657225 [doi]
AB  - BACKGROUND: There is still relatively limited data on psoriasis and hepatitis C 
      virus (HCV) infections. OBJECTIVE: This study investigated the clinical 
      characteristics and treatment of psoriasis patients with HCV infections in 
      real-world practice. METHODS: Medical records of all psoriasis patients with HCV 
      infections who attended the outpatient clinic at Siriraj Hospital over a 10-year 
      period were retrospectively reviewed. RESULTS: Of 34 patients, 26 and 8 patients 
      were men and women, respectively with a mean age of 57.0 +/- 8.7 (range, 42.2-77.2) 
      years. The median age of psoriasis onset was 42.7 +/- 12.7 (range, 8-67.25) years. 
      With a median follow-up period of 13.6 years, cirrhosis and hepatocellular 
      carcinoma were found in 67.6% and 29.4% of the patients, respectively. The 
      interferon used for HCV treatment exacerbated the psoriasis in 20% of those 
      patients. Conventional treatments and anti-tumor necrosis factors (anti-TNFs) 
      were used in strict collaboration with hepatologists. No patients experienced a 
      worsening of their HCV infection. CONCLUSION: Despite a limited number of 
      patients, a male predominance and late-onset psoriasis were frequently observed. 
      Although, interferon therapy for HCV can exacerbate psoriasis, it is not 
      contraindicated. All conventional treatments and anti-TNFs can be used, provided 
      that there is strict collaboration with hepatologists.
FAU - Chularojanamontri, Leena
AU  - Chularojanamontri L
AD  - Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Nimanong, Supot
AU  - Nimanong S
AD  - Division of Gastroenterology, Department of Medicine, Faculty of Medicine, 
      Siriraj Hospital, Mahidol University, Bangkok, Thailand.
FAU - Wongpraparut, Chanisada
AU  - Wongpraparut C
AD  - Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Silpa-Archa, Narumol
AU  - Silpa-Archa N
AD  - Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Chaiyabutr, Chayada
AU  - Chaiyabutr C
AD  - Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Charoenpipatsin, Norramon
AU  - Charoenpipatsin N
AD  - Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20190828
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 0 (Antiviral Agents)
RN  - 49717AWG6K (Ribavirin)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/*adverse effects/therapeutic use
MH  - Female
MH  - Hepatitis C/complications/*drug therapy
MH  - Humans
MH  - Interferons/adverse effects/therapeutic use
MH  - Liver Cirrhosis/etiology
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/complications/pathology
MH  - Retrospective Studies
MH  - Ribavirin/therapeutic use
MH  - Sustained Virologic Response
OTO - NOTNLM
OT  - Psoriasis
OT  - a retrospective study
OT  - hepatitis C
EDAT- 2019/08/17 06:00
MHDA- 2021/06/22 06:00
CRDT- 2019/08/17 06:00
PHST- 2019/08/17 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2019/08/17 06:00 [entrez]
AID - 10.1080/09546634.2019.1657225 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2021 May;32(3):321-327. doi: 10.1080/09546634.2019.1657225. 
      Epub 2019 Aug 28.